English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, March 17, 2021
DZNEとエーザイ、神経変性疾患の新規治療薬創出に向けた共同研究契約を締結
DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders
Tuesday, March 16, 2021
Eisai: Anti-MTBR (Microtubule Binding Region) Tau Antibody E2814 is Selected on Clinical Study for Dominantly Inherited Alzheimer's Disease by Dian-Tu
エーザイ、DIAN-TUは優性遺伝アルツハイマー病に対する臨床試験において、抗MTBR(Microtubule binding region: 微小管結合領域)タウ抗体E2814を選定
Friday, March 12, 2021
Eisai: Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anti-Cancer Agent Lenvima (Lenvatinib) With Prospective Indication for Uterine Body Cancer
エーザイ、抗がん剤「レンビマ(R)」(レンバチニブ)が日本において「予定される効能又は効果」としての子宮体がんについて、厚生労働省より希少疾病用医薬品に指定
Friday, March 5, 2021
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 15th International Conference on Alzheimer's and Parkinson's Disease
エーザイ、第15回アルツハイマー・パーキンソン病学会(AD/PD2021)においてアルツハイマー病/認知症領域の開発品に関する最新データを発表
Thursday, March 4, 2021
エーザイ、健康経営優良法人2021~ホワイト500~に認定
エーザイ、新型コロナウイルス感染症のケニアにおける検査体制の構築を支援

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575